Yither biotech (Shanghai) Co., Ltd

(1) Phase I To evaluate the safety and tolerability of recombinant herpes zoster vaccine (CHO cells) with different adjuvant doses in healthy people aged 40 years and above. (2) Phase II Main objectives 1) To evaluate the immunogenicity of recombinant herpes zoster vaccine (CHO cells) with different adjuvant doses in healthy people aged 40 years and above, and to provide a reference for the selection of adjuvant doses and immunization schedules in Phase III clinical trials. 2) To evaluate the safety of recombinant herpes zoster vaccine (CHO cells) with different adjuvant doses in healthy people aged 40 years and above. Secondary objectives To evaluate the immune persistence of recombinant herpes zoster vaccine (CHO cells) with different adjuvant doses in healthy people aged 40 years and above.